A universal system to select gene-modified hepatocytes in vivo

Science Translational Medicine

Volumn 8, Issue 342, 2016, Pages

  Nygaard, Sean ^a   Barzel, Adi ^b   Haft, Annelise ^a   Major, Angela ^c   Finegold, Milton ^c   Kay, Mark A ^b   Grompe, Markus ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYPHENYLPYRUVATE DIOXYGENASE; 4 [(2 CARBOXYETHYL)HYDROXYPHOSPHINYL] 3 OXOBUTYRATE; ADENOVIRUS VECTOR; ENZYME INHIBITOR; FUMARYLACETOACETASE; MESSENGER RNA; RECOMBINANT ADENO ASSOCIATED VIRAL VECTOR; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; HYDROLASE; MICRORNA; SMALL INTERFERING RNA;

ADULT; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL EXPANSION; CELL PROTECTION; CELL SELECTION; COMPARATIVE STUDY; CONTROLLED STUDY; DNA MODIFICATION; FEMALE; GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE LOCUS; GENE MODIFIED HEPATOCYTE; GENE SILENCING; GENE TARGETING; GENETIC BACKGROUND; HF9 GENE; IN VIVO STUDY; LIVER CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SEQUENCE HOMOLOGY; TRANSGENE; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; DEPENDOPARVOVIRUS; GENETICS; LIVER; METABOLISM; MUTANT MOUSE STRAIN;

ANIMALS; DEPENDOVIRUS; HEPATOCYTES; HYDROLASES; LIVER; MALE; MICE; MICE, MUTANT STRAINS; MICRORNAS; RNA, SMALL INTERFERING;

EID: 84973878623     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aad8166     Document Type: Article

References (47)

1. F. Mingozzi, K. A. High, Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges. Nat. Rev. Genet. 12, 341-355 (2011).
2. A. C. Nathwani, E. G. D. Tuddenham, S. Rangarajan, C. Rosales, J. McIntosh, D. C. Linch, P. Chowdary, A. Riddell, A. J. Pie, C. Harrington, J. O'Beirne, K. Smith, J. Pasi, B. Glader, P. Rustagi, C. Y. C. Ng, M. A. Kay, J. Zhou, Y. Spence, C. L. Morton, J. Allay, J. Coleman, S. Sleep, J. M. Cunningham, D. Srivastava, E. Basner-Tschakarjan, F. Mingozzi, K. A. High, J. T. Gray, U. M. Reiss, A. W. Nienhuis, A. M. Davidoff, Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med. 365, 2357-2365 (2011).
3. L. Wang, P. Bell, J. Lin, R. Calcedo, A. F. Tarantal, J. M. Wilson, AAV8-mediated hepatic gene transfer in infant rhesus monkeys (Macaca mulatta). Mol. Ther. 19, 2012-2020 (2011).
4. G. C. Pien, E. Basner-Tschakarjan, D. J. Hui, A. N. Mentlik, J. D. Finn, N. C. Hasbrouck, S. Zhou, S. L. Murphy, M. V. Maus, F. Mingozzi, J. S. Orange, K. A. High, Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors. J. Clin. Invest. 119, 1688-1695 (2009).
5. F. Mingozzi, K. A. High, Immune responses to AAV in clinical trials. Curr. Gene Ther. 7, 316-324 (2007).
6. C. S. Manno, G. F. Pierce, V. R. Arruda, B. Glader, M. Ragni, J. J. E. Rasko, M. C. Ozelo, K. Hoots, P. Blatt, B. Konkle, M. Dake, R. Kaye, M. Razavi, A. Zajko, J. Zehnder, P. Rustagi, H. Nakai, A. Chew, D. Leonard, J. F. Wright, R. R. Lessard, J. M. Sommer, M. Tigges, D. Sabatino, A. Luk, H. Jiang, F. Mingozzi, L. Couto, H. C. Ertl, K. A. High, M. A. Kay, Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12, 342-347 (2006).
7. P.-R. Wang, M. Xu, S. Toffanin, Y. Li, J. M. Llovet, D. W. Russell, Induction of hepatocellular carcinoma by in vivo gene targeting. Proc. Natl. Acad. Sci. U.S.A. 109, 11264-11269 (2012).
8. A. Donsante, D. G. Miller, Y. Li, C. Vogler, E. M. Brunt, D. W. Russell, M. S. Sands, AAV vector integration sites in mouse hepatocellular carcinoma. Science 317, 477 (2007).
9. J.-C. Nault, S. Datta, S. Imbeaud, A. Franconi, M.Mallet, G. Couchy, E. Letouzé, C. Pilati, B. Verret, J.-F. Blanc, C. Balabaud, J. Calderaro, A. Laurent, M. Letexier, P. Bioulac-Sage, F. Calvo, J. Zucman-Rossi, Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat. Genet. 47, 1187-1193 (2015).
10. N. K. Paulk, L. M. Loza, M. J. Finegold, M. Grompe, AAV-mediated gene targeting is significantly enhanced by transient inhibition of nonhomologous end joining or the proteasome in vivo. Hum. Gene Ther. 23, 658-665 (2012).
11. N. K. Paulk, K. Wursthorn, Z. Wang, M. J. Finegold, M. A. Kay, M. Grompe, Adeno-associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo. Hepatology 51, 1200-1208 (2010).
12. D. G. Miller, P.-R. Wang, L. M. Petek, R. K. Hirata, M. S. Sands, D. W. Russell, Gene targeting in vivo by adeno-associated virus vectors. Nat. Biotechnol. 24, 1022-1026 (2006).
13. H. Li, V. Haurigot, Y. Doyon, T. Li, S. Y.Wong, A. S. Bhagwat, N. Malani, X. M. Anguela, R. Sharma, L. Ivanciu, S. L. Murphy, J. D. Finn, F. R. Khazi, S. Zhou, D. E. Paschon, E. J. Rebar, F. D. Bushman, P. D. Gregory, M. C. Holmes, K. A. High, In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature 475, 217-221 (2011).
14. H. Yin, W. Xue, S. Chen, R. L. Bogorad, E. Benedetti, M. Grompe, V. Koteliansky, P. A. Sharp, T. Jacks, D. G. Anderson, Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat. Biotechnol. 32, 551-553 (2014).
15. H. Yin, C.-Q. Song, J. R. Dorkin, L. J. Zhu, Y. Li, Q. Wu, A. Park, J. Yang, S. Suresh, A. Bizhanova, A. Gupta, M. F. Bolukbasi, S. Walsh, R. L. Bogorad, G. Gao, Z. Weng, Y. Dong, V. Koteliansky, S. A. Wolfe, R. Langer, W. Xue, D. G. Anderson, Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nat. Biotechnol. 34, 328-333 (2016).
16. E. A. Kvittingen, H. Rootwelt, R. Berger, P. Brandtzaeg, Self-induced correction of the genetic defect in tyrosinemia type I. J. Clin. Invest. 94, 1657-1661 (1994).
17. Y. Yoshida, Y. Tokusashi, G. H. Lee, K. Ogawa, Intrahepatic transplantation of normal hepatocytes prevents Wilson's disease in Long-Evans cinnamon rats. Gastroenterology 111, 1654-1660 (1996).
18. J. Ding, G. R. Yannam, N. Roy-Chowdhury, T. Hidvegi, H. Basma, S. I. Rennard, R. J. Wong, Y. Avsar, C. Guha, D. H. Perlmutter, I. J. Fox, J. Roy-Chowdhury, Spontaneous hepatic repopulation in transgenic mice expressing mutant human a1-antitrypsin by wild-type donor hepatocytes. J. Clin. Invest. 121, 1930-1934 (2011).
19. J. M. L. De Vree, R. Ottenhoff, P. J. Bosma, A. J. Smith, J. Aten, R. P. J. Oude Elferink, Correction of liver disease by hepatocyte transplantation in a mouse model of progressive familial intrahepatic cholestasis. Gastroenterology 119, 1720-1730 (2000).
20. K. Overturf, M. Al-Dhalimy, R. Tanguay, M. Brantly, C.-N. Ou, M. Finegold, M. Grompe, Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I. Nat. Genet. 12, 266-273 (1996).
21. R. L. Bateman, P. Bhanumoorthy, J. F. Witte, R.W. McClard, M. Grompe, D. E. Timm, Mechanistic inferences from the crystal structure of fumarylacetoacetate hydrolase with a bound phosphorusbased inhibitor. J. Biol. Chem. 276, 15284-15291 (2001).
22. R. L. Bateman, J. Ashworth, J. F. Witte, L.-J. Baker, P. Bhanumoorthy, D. E. Timm, T. D. Hurley, M. Grompe, R. W. McClard, Slow-onset inhibition of fumarylacetoacetate hydrolase by phosphinate mimics of the tetrahedral intermediate: Kinetics, crystal structure and pharmacokinetics.Biochem. J. 402, 251-260 (2007).
23. N. K. Paulk, K. Wursthorn, A. Haft, C. Pelz, G. Clarke, A. H. Newell, S. B. Olson, C. O. Harding, M. J. Finegold, R. L. Bateman, J. F. Witte, R. McClard, M. Grompe, In vivo selection of transplanted hepatocytes by pharmacological inhibition of fumarylacetoacetate hydrolase in wild-type mice. Mol. Ther. 20, 1981-1987 (2012).
24. F. Endo, S. Kubo, H. Awata, K. Kiwaki, H. Katoh, Y. Kanegae, I. Saito, J.-i.Miyazaki, T. Yamamoto, C. Jakobs, S. Hattori, I. Matsuda, Complete rescue of lethal albino c14CoS mice by null mutation of 4-hydroxyphenylpyruvate dioxygenase and induction of apoptosis of hepatocytes in these mice by in vivo retrieval of the tyrosine catabolic pathway. J. Biol. Chem. 272, 24426-24432 (1997).
25. K.Manning, M. Al-Dhalimy, M. Finegold,M.Grompe, In vivo suppressormutations correct a murine model of hereditary tyrosinemia type I. Proc. Natl. Acad. Sci. U.S.A. 96, 11928-11933 (1999).
26. S. Lindstedt, E. Holme, E. A. Lock, O. Hjalmarson, B. Strandvik, Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 340, 813-817 (1992).
27. J. Larochelle, F. Alvarez, J.-F. Bussières, I. Chevalier, L. Dallaire, J. Dubois, F. Faucher, D. Fenyves, P. Goodyer, A. Grenier, E. Holme, R. Laframboise, M. Lambert, S. Lindstedt, B. Maranda, S. Melançon, A. Merouani, J. Mitchell, G. Parizeault, L. Pelletier, V. Phan, P. Rinaldo, C. R. Scott, C. Scriver, G. A. Mitchell, Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec. Mol. Genet. Metab. 107, 49-54 (2012).
28. L. Lisowski, A. Lau, Z. Wang, Y. Zhang, F. Zhang, M. Grompe, M. A. Kay, Ribosomal DNA integrating rAAV-rDNA vectors allowfor stable transgene expression.Mol. Ther. 20, 1912-1923 (2012).
29. Z. Wang, L. Lisowski, M. J. Finegold, H. Nakai, M. A. Kay, M. Grompe, AAV vectors containing rDNA homology display increased chromosomal integration and transgene persistence. Mol. Ther. 20, 1902-1911 (2012).
30. A. Barzel, N. K. Paulk, Y. Shi, Y. Huang, K. Chu, F. Zhang, P. N. Valdmanis, L. P. Spector, M. H. Porteus, K. M. Gaensler, M. A. Kay, Promoterless gene targeting without nucleases ameliorates haemophilia B in mice. Nature 517, 360-364 (2015).
31. R. J. Chandler, M. C. LaFave, G. K. Varshney, N. S. Trivedi, N. Carrillo-Carrasco, J. S. Senac, W. Wu, V. Hoffmann, A. G. Elkahloun, S. M. Burgess, C. P. Venditti, Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. J. Clin. Invest. 125, 870-880 (2015).
32. D. Grimm, K. L. Streetz, C. L. Jopling, T. A. Storm, K. Pandey, C. R. Davis, P. Marion, F. Salazar, M. A. Kay, Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441, 537-541 (2006).
33. C. E. Hill-Kayser, J. P. Plastaras, Z. Tochner, E. Glatstein, TBI during BM and SCT: Review of the past, discussion of the present and consideration of future directions. Bone Marrow Transplant. 46, 475-484 (2011).
34. S. Gerull, B. C. Beard, L. J. Peterson, T. Neff, H.-P. Kiem, In vivo selection and chemoprotection after drug resistance gene therapy in a nonmyeloablative allogeneic transplantation setting in dogs. Hum. Gene Ther. 18, 451-456 (2007).
35. J. E. Adair, S. K. Johnston, M. M. Mrugala, B. C. Beard, L. A. Guyman, A. L. Baldock, C. A. Bridge, A. Hawkins-Daarud, J. L. Gori, D. E. Born, L. F. Gonzalez-Cuyar, D. L. Silbergeld, R. C. Rockne, B. E. Storer, J. K. Rockhill, K. R. Swanson, H.-P. Kiem, Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients. J. Clin. Invest. 124, 4082-4092 (2014).
36. C. Mitchell, A. Mignon, J. E. Guidotti, S. Besnard, M. Fabre, N. Duverger, D. Parlier, A. Tedgui, A. Kahn, H. Gilgenkrantz, Therapeutic liver repopulation in a mouse model of hypercholesterolemia. Hum. Mol. Genet. 9, 1597-1602 (2000).
37. A. Mignon, J. E. Guidotti, C. Mitchell, M. Fabre, A. Wernet, A. De La Coste, O. Soubrane, H. Gilgenkrantz, A. Kahn, Selective repopulation of normal mouse liver by Fas/CD95-resistant hepatocytes. Nat. Med. 4, 1185-1188 (1998).
38. R. Jorquera, R. M. Tanguay, Cyclin B-dependent kinase and caspase-1 activation precedes mitochondrial dysfunction in fumarylacetoacetate-induced apoptosis. FASEB J. 13, 2284-2298 (1999).
39. D. W. Russell, M. Grompe, Adeno-associated virus finds its disease. Nat. Genet. 47, 1104-1105 (2015).
40. E. Holme, S. Lindstedt, Nontransplant treatment of tyrosinemia. Clin. Liver Dis. 4, 805-814 (2000).
41. L. Leung, A. S. Kalgutkar, R. S. Obach, Metabolic activation in drug-induced liver injury. Drug Metab. Rev. 44, 18-33 (2012).
42. T. J. Urban, A. K. Daly, G. P. Aithal, Genetic basis of drug-induced liver injury: Present and future. Semin. Liver Dis. 34, 123-133 (2014).
43. M. Grompe, M. Al-Dhalimy, M. Finegold, C.-N. Ou, T. Burlingame, N. G. Kennaway, P. Soriano, Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice. Genes Dev. 7, 2298-2307 (1993).
44. M. Grompe, S. Lindstedt, M. Al-Dhalimy, N. G. Kennaway, J. Papaconstantinou, C. A. Torres-Ramos, C. N. Ou, M. Finegold, Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I. Nat. Genet. 10, 453-460 (1995).
45. C. Fellmann, T. Hoffmann, V. Sridhar, B. Hopfgartner, M. Muhar, M. Roth, D. Y. Lai, I. A. M. Barbosa, J. S. Kwon, Y. Guan, N. Sinha, J. Zuber, An optimized microRNA backbone for effective singlecopy RNAi. Cell Rep. 5, 1704-1713 (2013).
46. D. Grimm, M. A. Kay, J. A. Kleinschmidt, Helper virus-free, optically controllable, and twoplasmid- based production of adeno-associated virus vectors of serotypes 1 to 6. Mol. Ther. 7, 839-850 (2003).
47. X. Wang, E. Montini, M. Al-Dhalimy, E. Lagasse, M. Finegold, M. Grompe, Kinetics of liver repopulation after bone marrow transplantation. Am. J. Pathol. 161, 565-574 (2002).